A Novel Hybrid Additive Manufacturing Process for Drug Delivery Systems with Locally Incorporated Drug Depots.

Jan Konasch,Natalia Rekowska,Thomas Eickner,Robert Mau,Alexander Riess,Hermann Seitz,Michael Teske,Niels Grabow

doi:10.3390/pharmaceutics11120661

Jan Konasch, Natalia Rekowska + Show 6 more

Open Access

https://doi.org/10.3390/pharmaceutics11120661

Copy DOI

Journal: Pharmaceutics	Publication Date: Dec 7, 2019
Citations: 19	License type: CC BY 4.0

Affiliation: University of Rostock

Abstract

Here, we present a new hybrid additive manufacturing (AM) process to create drug delivery systems (DDSs) with selectively incorporated drug depots. The matrix of a DDS was generated by stereolithography (SLA), whereas the drug depots were loaded using inkjet printing. The novel AM process combining SLA with inkjet printing was successfully implemented in an existing SLA test setup. In the first studies, poly(ethylene glycol) diacrylate-based specimens with integrated depots were generated. As test liquids, blue and pink ink solutions were used. Furthermore, bovine serum albumin labeled with Coomassie blue dye as a model drug was successfully placed in a depot inside a DDS. The new hybrid AM process makes it possible to place several drugs independently of each other within the matrix. This allows adjustment of the release profiles of the drugs depending on the size as well as the position of the depots in the DDS.

Highlights

Personalized drug therapy offers great potential to optimize treatments for every patient [1]
Here, we present a new hybrid additive manufacturing (AM) process to create drug delivery systems (DDSs) with selectively incorporated drug depots
The present study demonstrates the implementation of a new technical approach for a hybrid AM process for producing DDSs as well as a preliminary experimental result demonstrating the proof-of-concept

Summary

Introduction

Personalized drug therapy offers great potential to optimize treatments for every patient [1]. Conventional drug manufacturing techniques are limited in taking a patient’s individuality into account, which could result in inadequate treatment doses and/or adverse effects, which could be hazardous for pediatric and geriatric patient groups [2]. Additive manufacturing (AM), referred to as 3D printing, has gained much attention for offering beneficial opportunities to overcome such limitations. In the pharmaceutical field the technology is still at an early stage [1,5] It took until the year 2015 for the first 3D-printed drug Spritam® by Aprecia Pharmaceuticals (Blue Ash, OH, USA) to be approved by the United States Food and Drug Administration (FDA) [13]. Extensive research in recent years has shown immense opportunities in the creation of additive manufactured personalized medicines with respect to the patient’s individual characteristics such as age, weight, and pharmacogenetics [2]. Multifunctional drug delivery systems (DDSs) with flexible drug formulations for increased bioavailability and accelerated release characteristics, especially for oral, oromucosal, and topical drug therapeutics, have been demonstrated [1,2,5]

Methods

Results

Discussion

Conclusion